Bladder Cancer — Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Citation(s)
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor